XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Update

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totaling 19,218 shares, a decrease of 97.2% from the April 30th total of 680,467 shares. Currently, 1.2% of the company’s stock are sold short. Based on an average daily volume of 239,726 shares, the days-to-cover ratio is presently 0.1 days.

XTL Biopharmaceuticals Price Performance

NASDAQ:XTLB traded down $0.08 during mid-day trading on Friday, reaching $2.38. The stock had a trading volume of 6,659 shares, compared to its average volume of 1,271,984. The business’s 50 day moving average is $2.59 and its 200 day moving average is $5.35. XTL Biopharmaceuticals has a fifty-two week low of $2.12 and a fifty-two week high of $10.28. The stock has a market cap of $5.24 million, a P/E ratio of -3.72 and a beta of 1.64.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.